Aptevo files prospectus for resale of over 6.4 million warrant shares
The Seattle biotech registered shares tied to an August 12, 2026 private placement and warrant inducement, as its stock traded at $2.60 on Nasdaq.
SEC filing
Latest
4 stories
Thursday, September 3
Wednesday, August 26
Aptevo Therapeutics discloses $3.47 million private placement, registers warrant shares for resale
An August 12 warrant inducement and private placement raised about $4.5 million for Aptevo, which is now registering up to 6.4 million shares for resale.
SEC filing (2)
Friday, August 14
Aptevo reports frontline AML data for mipletamig, targets Phase 2 talks in early 2027
Aptevo said dose optimization for mipletamig should finish by year end 2026, ahead of a planned Phase 2 regulatory interaction in the first quarter of 2027.
SEC filing
Thursday, August 13
Aptevo closes $4.5 million warrant inducement and PIPE financing
The transactions, first announced August 12, 2026, closed August 13, 2026, with Roth Capital Partners as placement agent.
SEC filing